Pfizer's Redmond to head WebMD

Share this article:
Pfizer's Redmond to head WebMD
Pfizer's Redmond to head WebMD
WebMD had to go all the way up to 42nd Street to find its new CEO, Pfizer honcho Cavan Redmond.

Redmond was group president, Animal Health, Consumer Healthcare and Corporate Strategy at Pfizer – a gig that should give him some insight into both the consumer- and healthcare professional-facing sides of WebMD's business, as well as a keen understanding of what the site's advertisers want.

“As the biopharmaceutical commercial model continues to evolve, WebMD can capitalize on these changes,” said Redmond in a statement. “WebMD's digital reach to consumers and physicians is an important part of the industry's communications infrastructure and as the healthcare industry undergoes significant changes, there is tremendous opportunity for WebMD to better enable patients and physicians to engage with one another.”

Though still the biggest brand in online health, WebMD increasingly has company, from close competitors like Everyday Health to the raft of young and hungry startups looking to upend the more established players through video and mobile-centric offerings. Redmond's predecessor, longtime CEO Wayne Gattinella, resigned in February amid flagging ad sales and an aborted plan to sell the company. The dearth of new drug launches has hurt the firm, as has competition for consumer advertising from ad networks and social media players.

WebMD's brands include the eponymous consumer portal as well as Medscape, MedicineNet, emedicineHealth, RxList, and Medscape Education.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...